None of the molecular therapies approved for HCC work through selective inhibition of a single molecular abnormality, and tissue-based predictors of benefit from immune checkpoint inhibitors (ICI), such as PD-L1 expression and tumour mutational burden (TMB), lack predictive ability and are characterised by pre-analytic heterogeneity [2]. The gene discussed is CD274; the disease is neoplasm.